ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares Press release LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 14, 2017
ProQR Announces Proposed Public Offering of Ordinary Shares Press release LEIDEN, the Netherlands, Nov. November 13, 2017
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness Press release Key Updates November 13, 2017
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates November 09, 2017
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Oktober 31, 2017
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Oktober 24, 2017
ProQR to Present at the Chardan Inaugural Gene Therapy Conference Press release LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Oktober 06, 2017
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release Key updates September 25, 2017
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Press release Key updates September 21, 2017